文献速递免疫规划传染病防控与疫情报告

转化性疫苗接种:一种基于桦木醇佐剂的五价疫苗对抗COVID-19和流感并增强免疫

Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
PubMed 文献 · Vaccine · 2024-03-19

本文报道一种新型五价联合候选疫苗在小鼠中的结果,针对冠状病毒和流感抗原的平均抗体滴度与安慰剂相比差异有统计学意义;冠状病毒抗原可自主诱导免疫应答,且与部分流感抗原可能有协同增强免疫应答的作用。同一抗原组内平均抗体滴度无剂量依赖性差异,提示少量抗原即可诱导与高剂量疫苗制剂相当的免疫应答。该疫苗即将准备开展临床试验和大规模生产。

要点

  • 五价联合候选疫苗在小鼠中针对冠状病毒和流感抗原的平均抗体滴度与安慰剂相比差异有统计学意义。
  • 冠状病毒抗原可自主诱导免疫应答,不依赖联合疫苗中流感抗原的存在。
  • 同一抗原组内平均抗体滴度无剂量依赖性差异,提示少量抗原即可诱导与高剂量疫苗制剂相当的免疫应答。

核心结论

  • 五价联合候选疫苗在小鼠中显示针对冠状病毒和流感抗原的平均抗体滴度与安慰剂相比差异有统计学意义;冠状病毒抗原可自主诱导免疫应答,且与部分流感抗原有协同增强免疫应答的提示;该疫苗即将准备开展临床试验和大规模生产。

研究设计与样本

  • 本文报道一种新型五价联合候选疫苗在小鼠中的研究结果。

主要发现

  • 针对冠状病毒和流感抗原的平均抗体滴度与安慰剂相比差异有统计学意义。
  • 冠状病毒抗原可自主诱导免疫应答,不依赖联合疫苗中流感抗原的存在。
  • 联合疫苗中冠状病毒抗原的存在增强了对部分所研究流感抗原的免疫应答,提示这些抗原可能协同作用并引发增强的免疫应答。
  • 同一抗原组疫苗制剂内平均抗体滴度无剂量依赖性差异,提示少量冠状病毒和流感抗原即可诱导与高剂量疫苗制剂相当的免疫应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of an effective combined vaccine represents a crucial strategy for preventing outbreaks of infectious diseases and reducing the burden on healthcare resources. Developing a combined vaccine against both influenza and the coronavirus is a promising approach, but it is still in the early stages of development. This paper reports on a novel combined pentavalent candidate vaccine that has shown promising results in mice, with statistically significant differences in mean antibody titer against the coronavirus and the influenza antigens compared to placebo. We have shown that the coronavirus antigen is capable of inducing an immune response autonomously, regardless of the presence of the influenza antigens in a combined vaccine. On the other hand, the presence of the coronavirus antigen in a combined vaccine showed to enhance the immune response against some of the studied influenza antigens, suggesting that these antigens may act in synergy and elicit an enhanced immune response. The absence of dose-dependent difference in mean antibody titer within the same antigenic groups of vaccine preparations suggested that even small amounts of the coronavirus and the influenza antigens could induce an immune response just as good as high-dose vaccine preparations, which certainly has important safety and cost implications. The vaccine is soon to be ready for clinical trials and mass production.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Krasilnikov I, Isaev A, Djonovic M, et al. Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity. Vaccine. 2024. PMID: 38508927. doi:10.1016/j.vaccine.2023.11.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。